Excellos
Excellos Labs is a cell therapy CTDMO providing integrated donor-to-dose cGMP manufacturing services — from apheresis collection through cryopreservation — for pharmaceutical and biotech developers of adoptive cell therapies including CAR-T, TIL, and TCR therapies.
- Company typePrivate
- Founded2021
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Excellos does
Excellos Labs is a cell therapy Contract Testing, Development and Manufacturing Organization (CTDMO) founded in 2021 as an independent spinout of the San Diego Blood Bank and headquartered in downtown San Diego. The company provides an integrated donor-to-dose manufacturing model serving pharmaceutical and biotechnology developers of adoptive cell therapies, including TIL Therapy, autologous and allogeneic CAR-T/NK Therapies, and TCR Therapy for cancer and autoimmune indications. Core operations span customized apheresis donor cell collection, cell isolation and enrichment, genetic modification, transduction, expansion, fill/finish, and cryopreservation under cGMP conditions across five ISO 7 cleanroom suites.
Excellos firmographics
Firmographics- Name
- Excellos
- Legal name
- EXCELLOS, Inc.
- Website
- https://excellos.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Excellos Labs is a cell therapy CTDMO providing integrated donor-to-dose cGMP manufacturing services — from apheresis collection through cryopreservation — for pharmaceutical and biotech developers of adoptive cell therapies including CAR-T, TIL, and TCR therapies.
- Ownership category
- akta.pro rank
Excellos industry classification
Industry- Product category
- Cell Therapy Contract Development and Manufacturing (CDMO/CTDMO)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy CDMO (HLAGABAD)
- akta.pro secondary industries
- Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)
Keywords
Where Excellos is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Excellos business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Development and Manufacturing Services (CDMO): Provides continuum of services from donor recruitment to establishment of genetically modified working cell banks including apheresis donor cell collection, cell processing, cell isolation and enrichment, genetic modification, analysis, expansion, and cryopreservation. Services are contracted on a project basis with phase-appropriate engagement from pre-clinical through commercial stages.
- Cell Therapy Products Catalog: Sells biological products including Leukapheresis-derived products, cord blood units, PBMCs, T Cells (alpha beta, gamma delta), NK Cells, CD34+ cells, and others. Products available as RUI and GMP materials, fresh or cryopreserved, with extensive characterization data.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom CDMO Services - Quote-based pricing |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Excellos product offering
Product offeringCore offering
Excellos Labs operates as a cell therapy Contract Development and Manufacturing Organization (CTDMO) providing end-to-end services from donor collection through commercial cGMP manufacturing. The company offers a donor-to-dose model combining a consented, recallable donor pool with deep cell characterization, apheresis collection, cell isolation, transduction, expansion, cryopreservation, and QA/regulatory services under ISO 7 cleanroom conditions, alongside a product catalog of leukapheresis and cord blood-derived starting materials.
Product overview
Excellos Labs operates as a cell therapy Contract Testing, Development and Manufacturing Organization (CTDMO) with two integrated offerings: a product catalog of cell therapy starting materials and contract development manufacturing services. The product portfolio includes Leukopak, LRS Chambers, isolated cells from peripheral blood (PBMCs, T Cells, NK Cells, CD34+), isolated cells from cord blood, and cord blood units—available as research-use, RUI, or GMP-grade materials, fresh or cryopreserved. The services portfolio provides a continuum from donor recruitment through commercial GMP manufacturing, encompassing customized cell collections, cell isolation, process development, tech transfer, cGMP manufacturing, transduction, expansion, cryopreservation, storage, and stability testing. Both offerings share deep cell characterization capabilities including immune profiling, metabolic assessment, effector potential evaluation, HLA typing, and longitudinal donor data. The company operates as a fully integrated subsidiary of OrganaBio following the 2026 acquisition, spanning facilities in Miami and San Diego under a unified quality management system.
Differentiator
Problem solved
Functional benefit
Products and services
- Leukopak Leukapheresis-derived products collected from consented, recallable donors, available fresh or cryopreserved, serving as starting material for cell therapy manufacturing.
- LRS Chambers Products derived from Leukoreduction System (LRS) chambers, providing additional starting material options for cell therapy development.
- Isolated Cells from Peripheral Blood Isolated cells including PBMCs, T Cells (alpha beta, gamma delta), NK Cells, and CD34+ cells derived from peripheral blood for immunotherapy research and manufacturing.
- Isolated Cells from Cord Blood Isolated cells derived from cord blood units, providing an alternative starting material source for cell therapy manufacturing programs.
- Cord Blood Unit Whole cord blood units available as starting material for cell therapy manufacturing and research applications.
- GMP Products GMP-grade materials and cells manufactured under cGMP conditions in ISO 7 cleanrooms, available by custom order for clinical and commercial cell therapy programs.
- Customized Cell Collections Custom apheresis donor cell collection services with access to a consented, recallable donor pool with rich diversity in ethnicity, sex, and age for clinical trial starting materials.
- Cell Isolation Cell isolation and enrichment services including PBMC isolation, T cell isolation, NK cell isolation, and CD34+ cell selection for downstream cell therapy applications.
- Process Development and GMP Manufacturing End-to-end cGMP manufacturing services including process development, optimization, scale-up, cell transduction, expansion, fill-finish, and cryopreservation in ISO 7 cleanroom suites.
- Quality Assurance and Regulatory Comprehensive quality assurance including Quality by Design (QBD) and Manufacturing by Design (MBD) frameworks, with phase-appropriate regulatory compliance support for clinical and commercial programs.
- Cryopreservation and Storage Cryopreservation, long-term storage, and stability testing services for cell therapy products, including third-party cryopreservation capabilities.
Quantifiable outcome
- Reducing variabilities in clinical responses and increasing probability of success in trials through better starting material characterization
- +1 more outcomes
Companies that use Excellos
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles1 record
Excellos technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
Excellos partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- OrganaBiocoreOrganaBio acquired substantially all operating assets of Excellos Inc. to create a bicoastal cell therapy contract development and manufacturing organization (CTDMO). Excellos Labs operates as a fully integrated subsidiary of OrganaBio, maintaining its name while combining complementary capabilities and expanding geographic coverage across Miami, San Diego, San Francisco, and Irvine facilities.
- VitalantcoreStrategic partnership and investment from Vitalant, a major nonprofit blood and biotherapies organization. Collaboration focuses on enhancing donor profiles, sourcing, testing, and laboratory services for cell therapy development and manufacturing. Vitalant provides funding and logistical support to accelerate new product launch and donor characterization, aiming to improve efficacy and reduce costs of cell therapies.
Scale indicators3 records
Recent moves7 records
Expansion highlights6 records
Excellos competitors and assessment
Company assessmentBroad incumbents
- Lonza Cell & Gene Therapies: Lonza is one of the largest global CDMOs offering cell and gene therapy manufacturing services across autologous and allogeneic platforms. Comparable to Excellos as a contract manufacturer serving pharma and biotech cell therapy developers, but at vastly greater scale, geographic reach, and with broader service breadth.
- Catalent Cell Therapy Services: Catalent provides cell therapy development and manufacturing services including viral vector and cell processing for CAR-T and related modalities. Comparable as a CDMO serving the same pharma/biotech cell therapy developer base, but operating global commercial-scale GMP capacity versus Excellos' clinical-stage focus.
Direct peers
- OrganaBio: OrganaBio is a cell and tissue supplier and CTDMO focused on providing human-derived starting materials (PBMCs, bone marrow, cord blood) and cGMP manufacturing services. It is now Excellos' parent company post-2026 acquisition, with directly overlapping customer base and complementary capabilities in donor sourcing and cell processing.
- Discovery Life Sciences: Discovery Life Sciences provides human biospecimens, cell processing, and cGMP cell therapy manufacturing services. Comparable as a cell therapy CDMO with a donor-derived starting materials catalog alongside contract manufacturing — overlapping directly with Excellos' Leukopak and isolated cell product lines and CDMO services.
Emerging players
- Cellares: Cellares is an emerging cell therapy manufacturing automation company developing closed-system, scalable platforms (Cell Shuttle) intended to industrialize cell therapy production. Comparable as a CTDMO/automation player addressing the same scaling and consistency challenges in autologous and allogeneic cell therapy manufacturing that Excellos targets.
- RoslinCT: RoslinCT is a cell and gene therapy CDMO with cGMP manufacturing for autologous and allogeneic cell therapies, including CAR-T and iPSC-derived products. Comparable as a specialized, Phase 1-to-commercial CTDMO serving the same biotech customer profile as Excellos, with overlapping modality focus.
- Kytopen: Kytopen develops Flowfect, a non-viral cell engineering platform for scalable manufacturing of cell therapies. Comparable as an emerging technology partner in the cell therapy manufacturing value chain and an active collaborator with Excellos, addressing the same customers and modality shift toward non-viral cell engineering.
- Cellular Origins: Cellular Origins is an emerging cell therapy manufacturing automation company focused on scalable, closed-system production of cell therapies. Comparable as a CTDMO-adjacent technology player tackling manufacturing scale and cost challenges for autologous and allogeneic cell therapy developers — the same customer base Excellos serves.
- BioBridge Global: BioBridge Global operates GenCure and other subsidiaries providing cell and tissue services including apheresis, cell processing, and biomanufacturing. Comparable as a nonprofit-affiliated supplier of donor-derived starting materials and cell therapy services, with a similar institutional lineage to Excellos' San Diego Blood Bank roots.
Others
- IsoPlexis: IsoPlexis (now Standard BioTools' cell biology unit) provides single-cell proteomics tools used to characterize cell therapy products including CAR-T cells. Comparable as an enabling technology provider in the cell therapy characterization workflow that complements Excellos' Deep Cell Characterization Platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Excellos social profiles
Digital presenceExcellos compliance and trust
Trust signalCompliance1 record
Excellos financial estimates
Financial estimateRevenue estimate
Valuation estimate
Excellos leadership team
Management profileNumber of profiles
Profiles2 records
Excellos funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Excellos M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Excellos
What does Excellos do?
Excellos Labs operates as a cell therapy Contract Development and Manufacturing Organization (CTDMO) providing end-to-end services from donor collection through commercial cGMP manufacturing. The company offers a donor-to-dose model combining a consented, recallable donor pool with deep cell characterization, apheresis collection, cell isolation, transduction, expansion, cryopreservation, and QA/regulatory services under ISO 7 cleanroom conditions, alongside a product catalog of leukapheresis and cord blood-derived starting materials.
Is Excellos a public or private company?
Excellos is a private company. It is classified as corporate owned and is currently acquired.
When was Excellos founded?
Excellos was founded in 2021. It employs 11 to 50 people.
Where is Excellos based?
Excellos is headquartered in San Diego, United States, in the North America region.
How does Excellos make money?
Two revenue lines are on record. Contract Development and Manufacturing Services (CDMO) is the primary driver. The others are cell Therapy Products Catalog.
Who are Excellos's main competitors?
Broad incumbents on record are Lonza Cell & Gene Therapies and Catalent Cell Therapy Services. Direct peers are OrganaBio and Discovery Life Sciences. Emerging players are Cellares, RoslinCT, Kytopen, Cellular Origins and BioBridge Global. IsoPlexis is listed as an others.
Does Excellos have an API?
No public API is recorded for Excellos.
What industry is Excellos in?
Excellos's product category is Cell Therapy Contract Development and Manufacturing (CDMO/CTDMO). Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing). Its NAICS code is 325414 and its SIC code is 2836.